FibroGen to Report Second Quarter 2025 Financial Results
FibroGen (NASDAQ: FGEN) has scheduled its second quarter 2025 financial results announcement for Monday, August 11, 2025, after market close. The company will host a conference call and webcast presentation at 5:00 PM Eastern Time on the same day.
The event will feature the FibroGen management team presenting financial results and providing a business update, followed by a live Q&A session. Investors can access the audio webcast through the company's website, and dial-in details will be provided upon registration.
FibroGen (NASDAQ: FGEN) ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per luned¨¬ 11 agosto 2025, dopo la chiusura del mercato. La societ¨¤ terr¨¤ una conference call e una presentazione in webcast alle 17:00 ora della costa orientale degli Stati Uniti dello stesso giorno.
L'evento vedr¨¤ il team di gestione di FibroGen presentare i risultati finanziari e fornire un aggiornamento sull'attivit¨¤, seguito da una sessione di domande e risposte in diretta. Gli investitori potranno accedere all'audio webcast tramite il sito web dell'azienda, con i dettagli per la chiamata forniti al momento della registrazione.
FibroGen (NASDAQ: FGEN) ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el lunes 11 de agosto de 2025, despu¨¦s del cierre del mercado. La compa?¨ªa realizar¨¢ una llamada de conferencia y una presentaci¨®n en webcast a las 5:00 PM hora del Este del mismo d¨ªa.
El evento contar¨¢ con la participaci¨®n del equipo directivo de FibroGen, que presentar¨¢ los resultados financieros y proporcionar¨¢ una actualizaci¨®n del negocio, seguido de una sesi¨®n de preguntas y respuestas en vivo. Los inversores podr¨¢n acceder a la transmisi¨®n de audio a trav¨¦s del sitio web de la empresa, y se proporcionar¨¢n los detalles para la llamada tras la inscripci¨®n.
FibroGen (NASDAQ: FGEN)? 2025? 2?? ?? ?? ??? 2025? 8? 11? ??? ? ?? ?? ??????. ??? ?? ? ?? ??? ?? 5?? ???? ?? ???? ??????? ??? ?????.
?? ????? FibroGen ???? ?? ??? ???? ?? ??? ??????, ?? ??? ???? ??? ?????. ????? ?? ????? ?? ??? ????? ??? ? ???, ?? ? ?? ?? ??? ?????.
FibroGen (NASDAQ : FGEN) a programm¨¦ l'annonce de ses r¨¦sultats financiers du deuxi¨¨me trimestre 2025 pour le lundi 11 ao?t 2025, apr¨¨s la cl?ture des march¨¦s. La soci¨¦t¨¦ organisera une conf¨¦rence t¨¦l¨¦phonique et une pr¨¦sentation en webcast ¨¤ 17h00 heure de l'Est le m¨ºme jour.
L'¨¦v¨¦nement comprendra une pr¨¦sentation des r¨¦sultats financiers et une mise ¨¤ jour commerciale par l'¨¦quipe de direction de FibroGen, suivie d'une session de questions-r¨¦ponses en direct. Les investisseurs pourront acc¨¦der ¨¤ la diffusion audio via le site web de l'entreprise, avec les d¨¦tails d'acc¨¨s fournis lors de l'inscription.
FibroGen (NASDAQ: FGEN) hat die Ver?ffentlichung der Finanzergebnisse f¨¹r das zweite Quartal 2025 f¨¹r Montag, den 11. August 2025, nach B?rsenschluss, angek¨¹ndigt. Das Unternehmen wird am selben Tag um 17:00 Uhr Eastern Time eine Telefonkonferenz und eine Webcast-Pr?sentation abhalten.
Die Veranstaltung beinhaltet eine Pr?sentation der Finanzergebnisse und ein Gesch?ftsupdate durch das Management von FibroGen, gefolgt von einer Live-Fragerunde. Investoren k?nnen den Audio-Webcast ¨¹ber die Webseite des Unternehmens verfolgen; die Einwahldaten werden nach der Registrierung bereitgestellt.
- None.
- None.
SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc.?(NASDAQ: FGEN) will announce second quarter 2025 financial results on?Monday, August 11?after the markets close.?FibroGen?will also conduct a conference call on that day at?5:00 PM Eastern Time?with the investment community to further detail the company's corporate and financial performance.
Conference Call and Webcast Presentation
The FibroGen?management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call?. To access the call by phone, please?, and you will be provided with dial in details. A replay of the webcast will also be available for a limited time on the??page on FibroGen¡¯s website.
About?FibroGen
FibroGen, Inc.?is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (°®Èð׿?, EVRENZO?) is currently approved in?China,?Europe,?Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the?U.S.?FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit?.?
For Investor Inquiries:
David DeLucia, CFA
Senior Vice President and Chief Financial Officer
